Ro

Direct-to-consumer telehealth across weight loss (Ro Body, GLP-1s), men's health (Roman heritage: ED, hair loss), women's health/fertility (Rory, Modern Fertility), dermatology, and at-home diagnostics — vertically integrated from asynchronous telehealth visits through in-house pharmacy fulfillment (including non-sterile compounding operations in Illinois and Florida) and at-home phlebotomy (Workpath, Kit acquisitions). Since 2023 the business has re-centered on GLP-1 obesity care, and since 2025 on being the preferred telehealth front-end for branded obesity drugs from Novo Nordisk and Eli Lilly — carrying every new form factor (Wegovy injection and pill, Zepbound vials and KwikPen, Foundayo oral) at launch.

Stated: be the patient's trusted front door for high-quality, affordable care — "the unit of value is a repeatable clinical loop, not a consultation" — and accelerate the "pharm-to-table" model where manufacturers sell direct to consumers through Ro's care layer. Inferred: position as the neutral, compliance-clean distribution and care layer for branded obesity drugs (contrast with Hims's compounding fallout), win day-one launch rights for every new form factor (vials, pills, pens, multi-month subscriptions — now four for four including Foundayo), monetize real-world data with pharma (Amgen), quietly retain in-house compounding capacity for personalized non-GLP-1 medications while keeping GLP-1 marketing branded-only, and build a mainstream household brand via celebrity and Super Bowl marketing to expand beyond weight loss into general primary-care-like relationships. CEO publicly downplays an IPO, saying benefits of staying private are growing.

Deep, exclusive-feeling integrations with Novo Nordisk and Eli Lilly built on regulatory cleanliness (branded-first prescribing and marketing), a vertically integrated stack (telehealth + pharmacy + compounding + labs + home phlebotomy) that competitors must assemble piecemeal, a large longitudinal patient dataset now generating peer-reviewed evidence and pharma research deals, and a decade of DTC brand equity across men's health and now obesity care. The four-consecutive day-one GLP-1 launch record (Wegovy pill, multi-month Wegovy, Zepbound KwikPen, Foundayo) is itself becoming a self-reinforcing moat: manufacturers default to Ro for launches because Ro converts them fastest.